netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Chapter Links...
 Details...
03.04.02  Expand sub section  Allergen Immunotherapy
Bee and Wasp Allergen Extracts (Pharmalgen®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For the treatment of bee and wasp venom allergy a sper NICE TA246.

APCO March 2012.

 
Link  NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
   
Benralizumab (Fasenra®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating severe eosinophilic asthma as per NICE TA565.

Funded by specialised commissioning.

APCO May 2019.

 
Link  NICE TA565: Benralizumab for treating severe eosinophilic asthma
   
Grass pollen extract (Grazax®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Specialist prescribing only for paediatric patients with severe allergic rhinitis where other treatments have failed.

APCO January 2019.

 
   
Mepolizumab (Nucala®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For the treatment of:

  • Severe refractory eosinophilic asthma, as per NICE TA431.Funded by specialised commissioning (APCO March 2017)
  • Severe eosinophilic asthma, in line with NICE TA671. Funded by specialised commissiong (APCO March 2021)
 
Link  NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Link  NICE TA671: Mepolizumab for treating severe eosinophilic asthma
   
Reslizumab (Cinquil®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating severe eosinophilic asthma as per NICE TA479. 

Funded by specialised commissioning. 

APCO November 2017.

 
Link  NICE TA479: Reslizumab for treating severe eosinophilic asthma
   
03.04.02  Expand sub section  Omalizumab
Omalizumab (Xolair®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For the treatment of:

  • Severe persistent allergic asthma as per NICE TA133 (APCO May 2013).
  • Previously treated chronic spontaneous urticarial as per NICE TA339. Prior Approval required. APCO July 2015.

 
Link  NICE TA278: Omalizumab for treating allergic asthma
Link  NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
   
 ....
 Non Formulary Items
Grass and Tree Pollen Extract  (Pollinex®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
House dust mite allergen immunotherapy  (Mitizax®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary